Last reviewed · How we verify
NCT07164703
A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping
trial testing Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations. in Advanced Cholangiocarcinoma (Part 1) in 55 participants. Not yet recruiting.
1 October 2029
Quick facts
| Lead sponsor | Mao-Lin Yan |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 55 |
| Start date | 1 October 2025 |
| Primary completion | 1 October 2029 |
| Estimated completion | 31 October 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations. — full drug profile →
Conditions studied
- Advanced Cholangiocarcinoma (Part 1) — all drugs for Advanced Cholangiocarcinoma (Part 1) →
Sponsor
Mao-Lin Yan — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Cholangiocarcinoma (Part 1). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07164703
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07164703 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mao-Lin Yan
- Last refreshed: 10 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07164703.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing